Parsons A, Cohen T, Schwarz T, Stein K, Ophir S, Paredes Casado J
Antiviral Res. 2021; 193:105124.
PMID: 34197862
PMC: 9157689.
DOI: 10.1016/j.antiviral.2021.105124.
Dinet J, Tonnelet D, Le Cloirec J, Becker S, Bohn P
Nucl Med Commun. 2020; 41(10):1106-1107.
PMID: 32941391
PMC: 7553030.
DOI: 10.1097/MNM.0000000000001258.
Peruzza L, Shekhar M, Vinaya Kumar K, Swathi A, Karthic K, Hauton C
Sci Rep. 2019; 9(1):13509.
PMID: 31534145
PMC: 6751192.
DOI: 10.1038/s41598-019-49836-0.
McRae M
Tissue Barriers. 2016; 4(1):e1143543.
PMID: 27141423
PMC: 4836474.
DOI: 10.1080/21688370.2016.1143543.
Hu M, Patel S, Zhou T, Rohan L
J Control Release. 2015; 219:681-696.
PMID: 26278511
PMC: 4656065.
DOI: 10.1016/j.jconrel.2015.08.018.
E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers.
Guo M, Sun Y, Zhang Y, Bughio S, Dai X, Ren W
PLoS One. 2014; 9(1):e87781.
PMID: 24498193
PMC: 3909222.
DOI: 10.1371/journal.pone.0087781.
Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity.
Haraguchi S, Ho S, Morrow M, Goodenow M, Sleasman J
J Leukoc Biol. 2011; 90(4):653-60.
PMID: 21504949
PMC: 3409632.
DOI: 10.1189/jlb.0111-009.
Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells.
Valentin A, Morrow M, Poirier R, Aleman K, Little R, Yarchoan R
AIDS Res Hum Retroviruses. 2010; 26(1):79-88.
PMID: 20059395
PMC: 2858927.
DOI: 10.1089/aid.2009.0044.
Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations.
Benish R, Rodriguez B, Zimmerman P, Mehlotra R
Infect Genet Evol. 2009; 10(1):60-7.
PMID: 19819348
PMC: 4387876.
DOI: 10.1016/j.meegid.2009.09.018.
Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors.
Hulgan T, Donahue J, Smeaton L, Pu M, Wang H, Lederman M
Eur J Clin Pharmacol. 2009; 65(11):1081-8.
PMID: 19779705
PMC: 2873632.
DOI: 10.1007/s00228-009-0725-5.
Alteration of viral lipid composition by expression of the phospholipid floppase ABCB4 reduces HIV vector infectivity.
van Til N, Heutinck K, van der Rijt R, Paulusma C, van Wijland M, Markusic D
Retrovirology. 2008; 5:14.
PMID: 18241333
PMC: 2265746.
DOI: 10.1186/1742-4690-5-14.
Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy.
Kock K, Grube M, Jedlitschky G, Oevermann L, Siegmund W, Ritter C
Clin Pharmacokinet. 2007; 46(6):449-70.
PMID: 17518506
DOI: 10.2165/00003088-200746060-00001.
Updated clinical pharmacologic considerations for HIV-1 protease inhibitors.
Anderson P, Fletcher C
Curr HIV/AIDS Rep. 2005; 1(1):33-9.
PMID: 16091221
DOI: 10.1007/s11904-004-0005-z.
No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients.
Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H
Ann Clin Microbiol Antimicrob. 2005; 4:3.
PMID: 15659247
PMC: 548666.
DOI: 10.1186/1476-0711-4-3.
Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4.
Owen A, Chandler B, Bray P, Ward S, Hart C, Back D
J Virol. 2004; 78(21):12022-9.
PMID: 15479841
PMC: 523248.
DOI: 10.1128/JVI.78.21.12022-12029.2004.
P glycoprotein in human immunodeficiency virus type 1 infection and therapy.
Sankatsing S, Beijnen J, Schinkel A, Lange J, Prins J
Antimicrob Agents Chemother. 2004; 48(4):1073-81.
PMID: 15047504
PMC: 375313.
DOI: 10.1128/AAC.48.4.1073-1081.2004.
Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors.
Anderson P, Fletcher C
Curr Infect Dis Rep. 2001; 3(4):381-387.
PMID: 11470030
DOI: 10.1007/s11908-001-0079-3.